High glycolytic activity in tumor cells leads to increased lactate production, and the transport of lactate mediated by SLC16A3 contributes to an immunosuppressive microenvironment, reducing the efficacy of immune checkpoint inhibitors by impairing CD8+ T cell function. This evidence concerns the gene SLC16A3 and neoplasm.